MarketCapExport financials
Agios Pharmaceuticals (AGIO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Agios Pharmaceuticals Income Statement 2025-2010 | AGIO
Brief overview of revenue and earnings at Agios Pharmaceuticals
The overview follows changes across a five-year period. According to figures from Agios Pharmaceuticals, revenue changed from $203 million to $54 million over five years. Across the full period, sales moved by −73.4%; the average annual rate was −23.3%. The negative rate indicates weakening core operations.
Gross profit was $200 million at the start and $47.7 million at the end of the period (−76.2%). Costs absorbed a larger share of revenue over the period. Gross profit as a share of revenue changed from 98.6% to 88.3%. The business retained less gross profit from each unit of revenue.
Over the period, EBITDA shifted from −$327 million to −$467 million, a change of −43%. The operating result outpaced sales and points to improving efficiency. EBITDA margin moved from −160.7% to −864.2%. The business retained less EBITDA from each unit of revenue.
Net income moved from −$327 million at the start to −$413 million at the end. Larger losses indicate rising pressure on the business.
Market value was $3 billion at the start and $1.6 billion at the end. Lower capitalization reflects weaker investor expectations.
Overall conclusion
The financial trajectory is weak and requires a cautious interpretation. The overall view is constrained by a weaker final result, pressure on operating profitability and declining capitalization. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Agios Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.63 B | 1.89 B | 1.49 B | 1.42 B | 1.99 B | 2.99 B | 3.12 B | 2.96 B | 3.76 B | 1.59 B | 1.58 B | 3.9 B | 437 M | - | - | - |
Shares |
58 M | 56.8 M | 55.7 M | 54.8 M | 60.4 M | 69 M | 60 M | 57.4 M | 46.6 M | 39.1 M | 37.4 M | 33.7 M | 15.4 M | - | - | - |
Historical Prices |
28.1 | 33.3 | 26.8 | 25.9 | 32.9 | 43.3 | 47.8 | 46.1 | 57.2 | 41.7 | 64.9 | 112 | 23.9 | - | - | - |
Net Income |
-413 M | 674 M | -352 M | -232 M | 1.6 B | -327 M | -411 M | -346 M | -315 M | -198 M | -118 M | -53.5 M | -39.4 M | -20.1 M | -23.7 M | - |
Revenue |
54 M | 36.5 M | 26.8 M | 14.2 M | - | 203 M | 118 M | 94.4 M | 43 M | 69.9 M | 59.1 M | 65.4 M | 25.5 M | 25.1 M | 21.8 M | - |
Cost of Revenue |
6.34 M | 4.16 M | 2.88 M | 1.7 M | - | 2.8 M | 1.32 M | 1.4 M | - | - | - | - | - | - | - | - |
Gross Profit |
47.7 M | 32.3 M | 23.9 M | 12.5 M | - | 200 M | 117 M | 93 M | - | - | - | - | - | - | - | - |
Operating Income |
-472 M | -426 M | -391 M | -389 M | -378 M | -336 M | -316 M | -362 M | -321 M | -201 M | -119 M | -54.1 M | -38.9 M | -23 M | -16.6 M | - |
Interest Expense |
1.96 M | 6.49 M | 6.06 M | 6.75 M | 14.4 M | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-467 M | -420 M | -385 M | -381 M | -370 M | -327 M | -418 M | -355 M | -314 M | -195 M | -115 M | -52.8 M | -37.4 M | -21.8 M | -15.8 M | - |
Operating Expenses |
520 M | 458 M | 415 M | 402 M | 378 M | 536 M | 543 M | 455 M | 364 M | 271 M | 178 M | 119 M | 64.4 M | 48.1 M | 38.5 M | - |
General and Administrative Expenses |
180 M | 157 M | 120 M | 122 M | 121 M | 115 M | 132 M | 114 M | 71.1 M | 50.7 M | 36 M | 19.1 M | 9.93 M | 7.06 M | 7.22 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Agios Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
59.7 M | 59.5 M | 58.8 M | 126 K | 58.1 M | 57.9 M | 57.5 M | 98.1 K | 56.9 M | 56.8 M | 56.4 M | 91.7 M | 55.8 M | 55.6 M | 55.3 M | 55.1 M | 54.8 M | 54.8 M | 54.6 M | -2.06 M | 57 M | 61.1 M | 69.5 M | 92 M | 69.1 M | 69 M | 68.6 M | 1.33 M | 58.8 M | 58.7 M | 58.5 M | 260 K | 58 M | 57.7 M | 55.7 M | 736 K | 48.5 M | 46.7 M | 42.3 M | 1 M | 38.5 M | 38 M | 37.9 M | 37.7 M | 37.5 M | 37.3 M | 37.2 M | 37.1 M | 34.5 M | 33.6 M | 31.4 M | 31.2 M | 22.7 M | 3.72 M | 3.66 M | 3.62 M | 3.44 M | 3.36 M | - | - | - | - | - |
Net Income |
-65 M | -101 M | -99.1 M | -108 M | -103 M | -112 M | -89.3 M | -96.5 M | 948 M | -96.1 M | -81.5 M | -95.9 M | -91.3 M | -83.8 M | -81 M | 36.5 M | -81.7 M | -91.8 M | -94.8 M | -94.6 M | -88.8 M | -86.2 M | 1.87 B | -97.7 M | -99 M | -90.5 M | -40.3 M | -102 M | -106 M | -110 M | -93.1 M | -91.8 M | -94.7 M | -68.7 M | -90.8 M | -88.3 M | -77.1 M | -83.1 M | -66.2 M | -56.5 M | -62.8 M | -56 M | -23.2 M | -40.6 M | -40.3 M | -31.9 M | -4.96 M | -26.7 M | 3.7 M | -18.3 M | -12.2 M | -12.4 M | -11.2 M | -8.62 M | -7.23 M | -5.31 M | -4.64 M | -5.51 M | -4.63 M | - | - | - | - |
Revenue |
55.4 M | 44.7 M | 20.7 M | 20 M | 12.9 M | 12.5 M | 8.73 M | 10.7 M | 8.96 M | 8.62 M | 8.19 M | 7.1 M | 7.4 M | 6.71 M | 5.61 M | 4.31 M | 3.52 M | 5.58 M | 832 K | - | - | - | - | 44 M | 34.7 M | 37.3 M | 87.1 M | 35.4 M | 26 M | 26.2 M | 30.2 M | 30 M | 15.2 M | 40.4 M | 7.34 M | 9.8 M | 10.6 M | 11.3 M | 10.5 M | 22.6 M | 8.98 M | 6.98 M | 31.3 M | 6.22 M | 5.48 M | 13.2 M | 34.2 M | 14.6 M | 33.9 M | 8.41 M | 8.41 M | 6.74 M | 6.27 M | 6.3 M | 6.3 M | 6.28 M | 6.27 M | 6.29 M | 6.27 M | - | - | - | - |
Cost of Revenue |
2.52 M | 3 M | 1.32 M | 1.88 M | 1.68 M | 1.7 M | 1.08 M | 1.26 M | 783 K | 1.5 M | 627 K | 586 K | 633 K | 1.11 M | 554 K | 413 K | 517 K | 435 K | 339 K | - | - | - | - | -1.85 M | 638 K | 675 K | 533 K | 287 K | 393 K | 303 K | 334 K | 702 K | 695 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
52.9 M | 41.7 M | 19.4 M | 18.1 M | 11.2 M | 10.8 M | 7.64 M | 9.47 M | 8.18 M | 7.12 M | 7.56 M | 6.52 M | 6.77 M | 5.6 M | 5.06 M | 3.9 M | 3 M | 5.15 M | 493 K | - | - | - | - | 45.9 M | 34.1 M | 36.7 M | 86.6 M | 35.2 M | 25.6 M | 25.9 M | 29.9 M | 29.3 M | 14.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-77.2 M | -111 M | -110 M | -122 M | -117 M | -127 M | -107 M | -125 M | -103 M | -106 M | -92.1 M | -106 M | -101 M | -93.7 M | -90.6 M | -99.2 M | -91.1 M | -97.6 M | -101 M | -105 M | -91.2 M | -91.2 M | -91.2 M | -92.4 M | -80.3 M | -83.3 M | -87 M | -106 M | -109 M | -114 M | -97.5 M | -96.4 M | -99.2 M | -72.9 M | -94 M | -90.1 M | -79 M | -84.6 M | -67 M | -57.4 M | -63.5 M | -56.5 M | -23.6 M | -40.9 M | -40.5 M | -32.1 M | -5.2 M | -26.7 M | 3.21 M | -18.3 M | -12.3 M | -12.2 M | -11.1 M | -8.53 M | -7.05 M | -6.5 M | -5.11 M | -6.12 M | -5.26 M | - | - | - | - |
Interest Expense |
266 K | 119 K | 119 K | 113 K | 67 K | 523 K | 1.25 M | 1.62 M | 1.65 M | 1.58 M | 1.63 M | 1.71 M | 1.2 M | 1.64 M | 1.5 M | 1.36 M | 1.08 M | 1.34 M | 2.97 M | 3.27 M | 4.64 M | 6.52 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-77.2 M | -111 M | -110 M | -122 M | -117 M | -127 M | -107 M | -125 M | -103 M | -106 M | -92.1 M | -106 M | -101 M | -93.7 M | -90.6 M | -99.2 M | -91.1 M | -97.6 M | -101 M | -105 M | -91.2 M | -91.2 M | -91.2 M | -92.4 M | -80.3 M | -80.8 M | -84.6 M | -104 M | -107 M | -112 M | -95.5 M | -94.4 M | -97.4 M | -71.2 M | -92.3 M | -88.5 M | -77.4 M | -83 M | -65.5 M | -55.7 M | -62.1 M | -53.9 M | -22.3 M | -40.9 M | -38.3 M | -31 M | -4.82 M | -26.7 M | 4.21 M | -17.7 M | -12 M | -12.2 M | -9.97 M | -7.8 M | -6.7 M | -6.5 M | -4.25 M | -5.59 M | -5.26 M | - | - | - | - |
Operating Expenses |
130 M | 152 M | 129 M | 140 M | 128 M | 138 M | 114 M | 135 M | 111 M | 113 M | 99.6 M | 113 M | 108 M | 99.3 M | 95.7 M | 103 M | 94.1 M | 103 M | 102 M | 105 M | 91.2 M | 91.2 M | 91.2 M | 138 M | 114 M | 120 M | 174 M | 141 M | 135 M | 140 M | 128 M | 126 M | 114 M | 113 M | 103 M | 99.9 M | 90.4 M | 95.9 M | 77.6 M | 80.1 M | 72.5 M | 63.4 M | 54.9 M | 40.9 M | 46 M | 45.4 M | 39.4 M | 26.7 M | 30.7 M | 26.7 M | 20.7 M | 12.2 M | 17.3 M | 14.8 M | 13.3 M | - | 11.4 M | 12.4 M | - | - | - | - | - |
General and Administrative Expenses |
56.5 M | 51.5 M | 48.3 M | 51.6 M | 41.3 M | 45.9 M | 41.5 M | 51.7 M | 38.5 M | 35.5 M | 31 M | 35.3 M | 25.8 M | 30.4 M | 28.4 M | 32.8 M | 29.1 M | 28.3 M | 31.5 M | 31.5 M | 27.2 M | 29.2 M | 33.6 M | 25.9 M | 28.3 M | 29.2 M | 31.7 M | 4.81 M | 33 M | 32.4 M | 31.8 M | 31.9 M | 31.1 M | 26.6 M | 24.6 M | 22.7 M | 17.5 M | 16.1 M | 14.8 M | - | 11.9 M | 12.6 M | 10.8 M | - | 9.93 M | 8.93 M | 6.95 M | - | 5.17 M | 4.16 M | 3.29 M | - | 2.53 M | 1.84 M | 1.85 M | - | 1.58 M | 1.95 M | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Agios Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
USA
Russia
Niderland
Israel
Spain
Germany
Australia
Britain
